

Stefano BibbÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6244573/publications.pdf>

Version: 2024-02-01

67
papers

2,371
citations

279798

23
h-index

233421

45
g-index

68
all docs

68
docs citations

68
times ranked

3404
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of gut microbiome on immunotherapy efficacy in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	3.3	12
2	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. <i>Biomedicines</i> , 2022, 10, 843.	3.2	6
3	High Frequency of Glucose-6-Phosphate Dehydrogenase Deficiency in Patients Diagnosed with Celiac Disease. <i>Nutrients</i> , 2022, 14, 1815.	4.1	3
4	Risk Factors, Diagnosis, and Management of <i>Clostridioides difficile</i> Infection in Patients with Inflammatory Bowel Disease. <i>Microorganisms</i> , 2022, 10, 1315.	3.6	7
5	Metagenomic Changes of Gut Microbiota following Treatment of <i>Helicobacter pylori</i> Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or <i>Lactobacillus reuteri</i> . <i>Nutrients</i> , 2022, 14, 2789.	4.1	6
6	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 599-622.	3.0	41
7	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	8.1	5
8	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. <i>Digestive and Liver Disease</i> , 2021, 53, 1428-1432.	0.9	10
9	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. <i>Digestive and Liver Disease</i> , 2021, 53, 1527-1528.	0.9	0
10	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110258.	4.8	52
11	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	1.7	13
12	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	3.3	37
13	Fecal microbiota transplantation for recurrent <i>C. difficile</i> infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. <i>Gut Microbes</i> , 2021, 13, 1994834.	9.8	21
14	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	3.7	9
15	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020, 52, 1390-1395.	0.9	16
16	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. <i>Endoscopy International Open</i> , 2020, 08, E980-E984.	1.8	4
17	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	3.3	36
18	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.9	40

#	ARTICLE	IF	CITATIONS
19	Fecal Microbiota Signatures in Celiac Disease Patients With Poly-Autoimmunity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 349.	3.9	20
20	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. <i>Journal of Clinical Medicine</i> , 2020, 9, 1757.	2.4	65
21	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	12.1	110
22	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 343-351.	3.1	29
23	The Effect of <i>Lactobacillus reuteri</i> Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial*. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 387-391.	0.9	97
24	Microbiome: what intensivists should know. <i>Minerva Anestesiologica</i> , 2020, 86, 777-785.	1.0	11
25	Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 48-69.	2.2	3
26	The Rise and Fall of the Secular Trend in Body Height in Sardinia: An Age-Period-Cohort Analysis. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 183-190.	0.2	1
27	Reactive arthritis secondary to <i>Hafnia alvei</i> enterocolitis. <i>BMJ Case Reports</i> , 2019, 12, e228513.	0.5	4
28	Clinical features and natural history of idiopathic peptic ulcers: a retrospective case-control study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1315-1321.	1.5	8
29	Fecal microbiota transplant for <i>C.Âdifficile</i> infection: Just say yes. <i>Anaerobe</i> , 2019, 60, 102109.	2.1	8
30	Twice-â€œday PPI, tetracycline, metronidazole quadruple therapy with <i>Pylera</i> ® or <i>Lactobacillus reuteri</i> for treatment naïve or for retreatment of <i>Helicobacter pylori</i> . Two randomized pilot studies. <i>Helicobacter</i> , 2019, 24, e12659.	3.5	17
31	Role of Probiotics in <i>Helicobacter pylori</i> Eradication: Lessons from a Study of <i>Lactobacillus reuteri</i> Strains DSM 17938 and ATCC PTA 6475 (<i>Gastrus</i> ®) and a Proton-Pump Inhibitor. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2019, 2019, 1-8.	1.9	25
32	Coeliac disease: beyond genetic susceptibility and gluten. A narrative review. <i>Annals of Medicine</i> , 2019, 51, 1-16.	3.8	11
33	Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2019, 11, 2913.	4.1	32
34	Response to: Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease". <i>Mediators of Inflammation</i> , 2018, 2018, 1-2.	3.0	5
35	Constipation in the elderly from Northern Sardinia is positively associated with depression, malnutrition and female gender. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 797-802.	1.5	23
36	Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	62

#	ARTICLE	IF	CITATIONS
37	Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-4.	1.5	5
38	Tu1319 - Lactobacillus Reuteri and a PPI Alone Provide Approximately a 12% Additive Increase in H. Pylori Eradication. <i>Gastroenterology</i> , 2018, 154, S-932.	1.3	0
39	Cancer time trend in a population following a socio-economic transition: results of age-period-cohort analysis. <i>International Journal of Public Health</i> , 2017, 62, 407-414.	2.3	7
40	Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 337.e1-337.e3.	6.0	60
41	Chronic autoimmune disorders are increased in coeliac disease. <i>Medicine (United States)</i> , 2017, 96, e8562.	1.0	51
42	Is there a role for gut microbiota in type 1 diabetes pathogenesis?. <i>Annals of Medicine</i> , 2017, 49, 11-22.	3.8	73
43	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. <i>British Journal of Pharmacology</i> , 2017, 174, 1426-1449.	5.4	126
44	Fecal microbiota transplantation: past, present and future perspectives. <i>Minerva Gastroenterology</i> , 2017, 63, 420-430.	0.5	22
45	Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients. <i>Medicine (United States)</i> , 2016, 95, e3411.	1.0	15
46	P.12.2 DIAGNOSIS OF CELIAC DISEASE IN ADULTS WITHOUT DUODENAL BIOPSY IN THE PRESENCE OF POSITIVE ANTI-ENDOMYSIUM ANTIBODIES AND ANTI-TRANSGLUTAMINASE ANTIBODIES. <i>Digestive and Liver Disease</i> , 2016, 48, e185.	0.9	0
47	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. <i>Digestive and Liver Disease</i> , 2016, 48, 1043-1047.	0.9	6
48	P.08.11 THE POSITION WITHIN THE OESOPHAGEAL CIRCUMFERENCE PREDICTS DYSPLASIA IN SHORT SEGMENT BARRETT'S ESOPHAGUS: A 7-YEAR RETROSPECTIVE SERIES OF 341 LESIONS. <i>Digestive and Liver Disease</i> , 2016, 48, e168-e169.	0.9	0
49	OC.12.9 FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT C. DIFFICILE INFECTION: A 2-YEAR EXPERIENCE FROM A EUROPEAN REFERRAL CENTRE. <i>Digestive and Liver Disease</i> , 2016, 48, e118.	0.9	0
50	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e139.	2.5	19
51	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.9	17
52	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 835-843.	3.7	467
53	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. , 2015, 149, 191-212.		139
54	Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. <i>Computers in Biology and Medicine</i> , 2015, 65, 308-314.	7.0	11

#	ARTICLE	IF	CITATIONS
55	Tu1533 Esophageal Posterior and Right Wall Are the Most Common Localizations of Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB499.	1.0	0
56	Tu1363 An Open-Label, Pilot Study to Assess Feasibility and Safety of Fecal Microbiota Transplantation in Patients With Mild-Moderate Ulcerative Colitis: Preliminary Results. <i>Gastroenterology</i> , 2015, 148, S-870.	1.3	7
57	Sa1301 High Rates of Prior Celiac Disease Overdiagnosis Among Patients Referring to an Italian Tertiary Care Center. <i>Gastroenterology</i> , 2015, 148, S-286.	1.3	0
58	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2014, 93, e97.	1.0	77
59	Systematic review: sprue-like enteropathy associated with olmesartan. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 16-23.	3.7	117
60	Letter: telmisartan associated enteropathy “is there any class effect? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 570-570.	3.7	15
61	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	43
62	OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS. <i>Digestive and Liver Disease</i> , 2014, 46, S26-S27.	0.9	0
63	OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION. <i>Digestive and Liver Disease</i> , 2014, 46, S35.	0.9	0
64	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. <i>Internal and Emergency Medicine</i> , 2014, 9, 365-373.	2.0	98
65	Fecal Microbiota Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S80-S84.	2.2	33
66	Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. <i>Current Drug Targets</i> , 2014, 15, 762-770.	2.1	74
67	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 5205.	3.3	38